Mitchell Feinman
Rheumatology · Orangeburg, SCNPI 1841479623
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,890 of the $29,610 with a category attached, or 63.8%. Amgen accounts for 75.8% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $11,988 and has fallen 99.8% since, to $20 in 2023.
Across 441 payments — averaging $67.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$22K
- UCB Biosciences Inc.$2K
- Pfizer$812
- UCB, Inc.$665
- Novartis$563
- Johnson & Johnson$543
- plus $3K from 20 others
Across 119 payments — averaging $6696.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$428K
- Gilead$212K
- UCB SA$65K
- E.r. Squibb & Sons, L.L.C.$55K
- Pfizer$28K
- Amgen$8K
- plus $2K from 2 others
What the payments were for
- Speaking & faculty fees$18,89064%
- Travel & lodging$2,7349%
- Food & beverage$7,98427%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 135 | $22,452 |
| UCB Biosciences Inc. | 9 | $1,796 |
| Pfizer | 46 | $812 |
| UCB, Inc. | 35 | $665 |
| Novartis | 30 | $563 |
| Johnson & Johnson | 33 | $543 |
| AbbVie | 27 | $431 |
| Lilly USA, LLC | 26 | $410 |
| E.r. Squibb & Sons, L.L.C. | 19 | $339 |
| AstraZeneca(2 entities) | 16 | $267 |
| GSK | 11 | $229 |
| Radius Health, Inc. | 13 | $221 |
| Regeneron Healthcare Solutions, Inc. | 10 | $201 |
| Genentech USA, Inc. | 7 | $135 |
| Merck | 6 | $92 |
| Aurinia Pharma U.S., Inc. | 3 | $78 |
| Gilead | 1 | $67 |
| Octapharma USA, Inc. | 1 | $59 |
| Regeneron | 1 | $50 |
| Hikma Pharmaceuticals USA | 3 | $41 |
| Bristol Myers Squibb | 2 | $38 |
| Organon | 2 | $35 |
| Boehringer Ingelheim | 2 | $30 |
| Tersera Therapeutics LLC | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$20,197
How this compares
$29,610 in reported general payments places this provider in the 85th percentile of 123 rheumatology providers in South Carolina.
Other rheumatology in Orangeburg
- Colin EdgertonSummerville$3.5M
- Gregory NiemerSummerville$2.9M
- Gary FinkSummerville$2.9M
- Clarence LegertonSummerville$2.9M
- Jennifer MurphySummerville$2.8M
- William EdwardsSummerville$1.3M
- Alan BrownGreenville$947K
- Douglas ConawayMyrtle Beach$500K
- Long Huynh-DucGreenville$278K
- Robert KeenanFlorence$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.